Pharmaceutical

AusperBio secures funding to advance AHB-137 for CHB

AusperBio has raised $37m in a Series A financing round to progress the clinical development of AHB-137 for chronic hepatitis B (CHB).

Jul 16, 2024 - 04:00
AusperBio secures funding to advance AHB-137 for CHB
AusperBio has raised $37m in a Series A financing round to progress the clinical development of AHB-137 for chronic hepatitis B (CHB).
Read the original article

Tags:

Previous Article

Exploring Melbourne’s booming life sciences sector

Next Article

Mabwell’s 9MW2821 gains FDA fast track status for breast cancer

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Biosyngen receives FDA approval to start Phase I trial for TCR therapy

Biosyngen receives FDA approval to start Phase I trial ...

Sep 11, 2023

BMS licenses TCR-T immunotherapy therapy from Immatics

BMS licenses TCR-T immunotherapy therapy from Immatics

May 2, 2023

STAT+: Nuance’s mysterious pricing, speedier digital health evidence reviews, and new breakthrough devices

STAT+: Nuance’s mysterious pricing, speedier digital he...

Jun 4, 2023